Home » News » CROs/Service Providers » Oracle to Acquire Relsys

Oracle to Acquire Relsys

Wednesday, March 25, 2009

Business software company Oracle has agreed to acquire Relsys, a provider of drug safety and risk management applications, for an undisclosed amount. The deal is expected to close by summer.

Relsys, which supports adverse event reporting, risk management and data analysis for drug and medical device developers and contract research organizations, will becomes a part of Oracle’s Health Sciences Global Business Unit.

Through this acquisition, Oracle hopes to deliver a suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care.

“The health sciences industry is increasing investments in software that provide greater transparency into drug safety and help improve the overall safety of therapies,” said Neil de Crescenzo, senior vice president and general manager of Oracle Health Sciences, in a company statement. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!